This trial looked at whether a nuclear imaging agent could be used to detect a protein associated with RA, compared to the current standard of looking at synovial tissue under a microscope.
- Rheumatoid Arthritis
1 Primary · 3 Secondary · Reporting Duration: Through study completion, up to 45 days
Side Effects for
Awards & Highlights
1 Treatment Group
RA Subjects on Stable Therapy
1 of 1
24 Total Participants · 1 Treatment Group
Primary Treatment: Tc 99m tilmanocept · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many individuals are being asked to take part in this clinical trial?
"Indeed, the information available on clinicaltrials.gov indicates that this trial is presently looking for 24 participants at 2 sites. The trial was first posted on 9/14/2021 and has been edited as recently as 9/13/2022." - Anonymous Online Contributor
Can people currently sign up for this experiment?
"According to the public clinicaltrials.gov website, this study is still recruiting patients. The listing for this trial was first created on September 14th, 2021 and has been edited as recently as September 13th, 2022." - Anonymous Online Contributor
Is Tc 99m tilmanocept a common medication used in clinical trials?
"Currently, there are 3 clinical trials involving Tc 99m tilmanocept. 0 of these ongoing studies have progressed to Phase 3 testing. While the majority of research is being conducted in London and California, 8 different states are running active trials." - Anonymous Online Contributor
Tc 99m tilmanocept is most commonly associated with which medical procedures?
"Tc 99m tilmanocept is a diagnostic imaging agent used to treat patients with malignant melanoma of the skin or breast cancer." - Anonymous Online Contributor
Are there any harmful effects to Tc 99m tilmanocept?
"Tc 99m tilmanocept's Phase 2 status means that, while there is some evidence suggesting it is safe, there is no data yet affirming its efficacy. Therefore, our team has given it a safety score of 2." - Anonymous Online Contributor